{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276000","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.181133+00:00","generated_at":"2026-05-16T21:19:13.592767+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study","bullets":["Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.","Overall response rate of 34% (35/103 patients) in Phase 2 PYNNACLE study; 46% ORR in ovarian cancer cohort with median duration of response of 8.0 months.","Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.","Net loss for Q3 2025 was $21.1M vs $19.2M in Q3 2024, driven by increased R&D costs of $18.2M.","R&D expenses increased to $18.2M from $16.9M due to advancement of rezatapopt program; G&A decreased to $4.3M from $4.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276000","json":"https://secwatch.observer/filing/0001193125-25-276000.json","markdown":"https://secwatch.observer/filing/0001193125-25-276000.md","text":"https://secwatch.observer/filing/0001193125-25-276000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/0001193125-25-276000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/pmvp-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:19:13.592767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}